Industry Explorers Blaze On

  1. What Life Sciences Startups Can Do About Market Swings 7/3/2023

    Ongoing capital needs that can span a decade or more mean that life sciences companies need the ability to navigate every season of market conditions. This requires strategic and long-term planning — and possibly some out-of-the-box thinking to ensure consistent funding well into the future.

  2. Debunking BYOD Myths In Clinical Trials 7/3/2023

    By adopting BYOD, life sciences can expand the collection of quality data sets during clinical trials to drive the development and approval of life-changing therapies for the patients that need them.

  3. Inside M&A With Bill Symonds 7/3/2023

    On episode 143 of the Business of Biotech, Enzyvant CEO Bill Symonds, Pharm.D. takes us inside the rationale and execution of last year’s Enzyvant/Altavant merger.

  4. India's CROs & CDMOs Come Of Age In The Global Marketplace 7/3/2023

    While a low price is the initial attraction for many American and European companies looking at India’s life sciences ecosystem, there are many additional factors that can be more meaningful.

  5. New Ways To Approach Your Next Tech Transfer 7/3/2023

    This article discusses the relatively new technological tools for technology transfer between sponsors and decentralized manufacturing sites or CDMOs, including electronic batch records (EBRs), laboratory information management systems (LIMS), automated monitoring, analytics, and process optimization tools.

  6. Cell & Gene Therapies Manufacturing Market Outlook 7/3/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition), we asked respondents to rank their top three satisfaction drivers regarding a CDMO’s performance in cell and/or gene manufacturing activities.

  7. Companies To Watch: Kinaset Therapeutics 7/3/2023

    Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.

  8. What Strategies Can Biotech Executives Use To Effectively Prioritize And De-Risk Development Programs During Tough Economic Times? 7/3/2023

    See the answer from Charlene Banard, the former EVP, chief technical officer at Atara Biotherapeutics.

  9. FDA's Digital Health Technologies Framework Addresses Important Challenges 7/3/2023

    In March 2023, CDER and CBER published a Framework for the Use of Digital Health Technologies (DHTs) in Drug and Biological Product Development (the “Framework”) to “guide the use of DHT-derived data in regulatory decision making for drugs and biological products.” Here is what you need to know.

  10. Ways To Face New Bio Funding & Banking Risks 7/3/2023

    Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.